Tradestie Institutional Equity Comparison Engine
BGLC vs CLBR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BGLC Overall Edge
BGLC Captures Institutional Edge (1โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioNexus Gene Lab Corp Common stock (BGLC) driven by superior Growth & Margin while CLBR counters with relative strength in Momentum & Technical. Fundamentally, BGLC trades at N/M Forward P/E with -88.2% operating margin (-96.6% YoY revenue) versus CLBR at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BGLC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLBR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BGLC N/M vs CLBR N/M Fwd P/E
Growth & Margin Winner
BGLC
Op Margin -88.2% vs N/A ยท YoY -96.6% vs N/A
Momentum & Technical Winner
CLBR
1Y -85.0% vs -0.5% ยท 52W Pos 1% vs 5%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGLC
NASDAQ
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.68
+0.0% 1D
Market Cap
$2.0M
1M Return
-42.86%
1Y Return
-84.99%
Forward P/E
N/M
Unified AI Score
44.2 / 100
HOLD
Tech 45.0
Fund 42.0
Flow 50.0
Mom 63.9
CLBR
US Equity
CLBR
Institutional Equity
$10.02
-0.1% 1D
Market Cap
N/A
1M Return
-0.4%
1Y Return
-0.5%
Forward P/E
N/M
Unified AI Score
47.5 / 100
HOLD
Tech 50.0
Fund 54.0
Flow 50.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BGLC -84.99%
CLBR -0.5%
Spread: +70.54 pp (CLBR Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BGLC TTM Op. Margin: -88.2%
CLBR TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGLC vs CLBR. Trailing 12-month operating profitability (BGLC -88.2% vs CLBR N/A) and valuation multiples (BGLC N/M vs CLBR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BGLC | CLBR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.0M | N/A | Larger Scale | BGLC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -96.6% | N/A | Higher Growth | BGLC |
| Operating Margin (TTM) Profitability | -88.2% | N/A | Higher Margin | BGLC |
| Net Profit Margin Profitability | -82.4% | N/A | Higher Margin | BGLC |
| Return on Equity (ROE) Capital Efficiency | -33.7% | N/A | Higher ROE | BGLC |
| 52-Week Range Position Momentum | 1% ($1โ$5) | 5% ($10โ$10) | Stronger Trend | CLBR |
| Beta / 30D Volatility Risk Regime | 1.34ฮฒ ยท 86% Vol | 0.08ฮฒ ยท 4% Vol | Lower Realized Risk | CLBR |
| Unified Institutional Score Composite Signal | 44.2 / 100 (HOLD) | 47.5 / 100 (HOLD) | Higher Composite | CLBR |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BGLC vs CLBR Buy Guide
BGLC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLBR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BGLC nor CLBR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.